Patents by Inventor Tsuyoshi Maekawa
Tsuyoshi Maekawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11518763Abstract: A compound represented by the following formula (I): wherein each symbol in the formula is as described herein or a salt thereof has an NRF2 activating activity, and is expected to be useful as a preventive or therapeutic agent for diseases associated with oxidative stress, in particular, hepatic disease (for example, non-alcoholic steatohepatitis (NASH)), cardiovascular disease (for example, heart failure or pulmonary arterial hypertension), lung disease (for example, chronic obstructive pulmonary disease (COPD)), kidney disease (for example, chronic kidney disease (CKD) or acute kidney injury (AKI)), central nervous system disease (for example, Parkinson's disease), mitochondrial disease (for example, Friedreich motor ataxia, mitochondrial myopathy), inflammatory disease (for example, multiple sclerosis (MS), inflammatory bowel disease (IBD)), sickle cell disease, cancer, or the like.Type: GrantFiled: December 4, 2019Date of Patent: December 6, 2022Assignee: SCOHIA PHARMA, INC.Inventors: Shigemitsu Matsumoto, Ryoma Hara, Naoyoshi Noguchi, Hideto Fukushi, Ayumu Niida, Satoshi Sasaki, Minoru Ikoma, Toshitake Kobayashi, Tsuyoshi Maekawa
-
Publication number: 20220119391Abstract: Compounds represented by the following formula (I): wherein each symbol in the formula is as described herein, or a salt thereof, and compositions comprising the same, and methods of using the same as an NRF2 activator and/or a preventive or therapeutic agent for diseases associated with oxidative stress, in particular, hepatic disease (for example, non-alcoholic steatohepatitis (NASH)), cardiovascular disease (for example, heart failure or pulmonary arterial hypertension), lung disease (for example, chronic obstructive pulmonary disease (COPD)), kidney disease (for example, chronic kidney disease (CKD) or acute kidney injury (AKI)), central nervous system disease (for example, Parkinson's disease), mitochondrial disease (for example, Friedreich motor ataxia, mitochondrial myopathy), inflammatory disease (for example, multiple sclerosis (MS), inflammatory bowel disease (IBD)), sickle cell disease, cancer, or the like.Type: ApplicationFiled: December 4, 2019Publication date: April 21, 2022Applicant: SCOHIA PHARMA, INC.Inventors: Shigemitsu MATSUMOTO, Ryoma HARA, Naoyoshi NOGUCHI, Hideto FUKUSHI, Ayumu NIIDA, Satoshi SASAKI, Minoru IKOMA, Toshitake KOBAYASHI, Tsuyoshi MAEKAWA
-
Publication number: 20210403420Abstract: The present invention provides a benzoic acid ester compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. A compound represented by the formula (I) or a salt thereof has an enteropeptidase inhibitory effect and is useful as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like: [in the formula, each symbol is as defined in the specification].Type: ApplicationFiled: August 26, 2019Publication date: December 30, 2021Inventors: Ryoma HARA, Kohei ASANO, Ayumu NIIDA, Shizuo KASAI, Tsuyoshi MAEKAWA
-
Patent number: 11186565Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.Type: GrantFiled: March 29, 2018Date of Patent: November 30, 2021Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Seiji Miwatashi, Yasufumi Miyamoto, Koji Watanabe, Yayoi Nakayama, Yuko Hitomi, Jumpei Aida, Nobuyuki Takakura, Hideki Furukawa, Naoyoshi Noguchi, Yasuhiro Hirata, Kazuaki Takami, Norihito Tokunaga, Tomohiro Okawa, Akito Shibuya, Shizuo Kasai, Toshitake Kobayashi, Tsuyoshi Maekawa
-
Patent number: 10968231Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.Type: GrantFiled: March 29, 2018Date of Patent: April 6, 2021Assignees: SCOHIA PHARMA, INC., TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Seiji Miwatashi, Yasufumi Miyamoto, Koji Watanabe, Yayoi Nakayama, Yuko Hitomi, Jumpei Aida, Nobuyuki Takakura, Hideki Furukawa, Naoyoshi Noguchi, Yasuhiro Hirata, Shizuo Kasai, Toshitake Kobayashi, Tsuyoshi Maekawa, Satoshi Sasaki, Shigemitsu Matsumoto
-
Publication number: 20200377509Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.Type: ApplicationFiled: March 29, 2018Publication date: December 3, 2020Applicants: TAKEDA PHARMACEUTICAL COMPANY LIMITED, SCOHIA PHARMA, INCInventors: Seiji MIWATASHI, Yasufumi MIYAMOTO, Koji WATANABE, Yayoi NAKAYAMA, Yuko HITOMI, Jumpei AIDA, Nobuyuki TAKAKURA, Hideki FURUKAWA, Naoyoshi NOGUCHI, Yasuhiro HIRATA, Shizuo KASAl, Toshitake KOBAYASHI, Tsuyoshi MAEKAWA, Satoshi SASAKI, Shigemitsu MATSUMOTO
-
Publication number: 20200039957Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.Type: ApplicationFiled: March 29, 2018Publication date: February 6, 2020Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Seiji MIWATASHI, Yasufumi MIYAMOTO, Koji WATANABE, Yayoi NAKAYAMA, Yuko HITOMI, Jumpei AIDA, Nobuyuki TAKAKURA, Hideki FURUKAWA, Naoyoshi NOGUCHI, Yasuhiro HIRATA, Kazuaki TAKAMI, Norihito TOKUNAGA, Tomohiro OKAWA, Akita SHIBUYA, Shizuo KASAl, Toshitake KOBAYASHI, Tsuyoshi MAEKAWA
-
Patent number: 9365540Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.Type: GrantFiled: January 11, 2013Date of Patent: June 14, 2016Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Shizuo Kasai, Hideyuki Igawa, Masashi Takahashi, Tsuyoshi Maekawa, Keiko Kakegawa, Asato Kina, Jumpei Aida, Uttam Khamrai, Mrinalkanti Kundu
-
Patent number: 9115136Abstract: Provided is a novel compound represented by the following formula wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor ? agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or metabolic diseases such as diabetes and the like, and the like.Type: GrantFiled: October 22, 2013Date of Patent: August 25, 2015Assignee: Takeda Pharmaceutical Company LimitedInventors: Tsuyoshi Maekawa, Hideyuki Igawa
-
Publication number: 20150018363Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.Type: ApplicationFiled: January 11, 2013Publication date: January 15, 2015Inventors: Shizuo Kasai, Hideyuki Igawa, Masashi Takahashi, Tsuyoshi Maekawa, Keiko Kakegawa, Tsuneo Yasuma, Asato Kina, Jumpei Aida, Uttam Khamrai, Mrinalkanti Kundu
-
Patent number: 8921379Abstract: Provided is a novel compound represented by the following formula Wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor ? agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or metabolic diseases such as diabetes and the like, and the like.Type: GrantFiled: August 9, 2011Date of Patent: December 30, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Tsuyoshi Maekawa, Hideyuki Igawa
-
Publication number: 20140046056Abstract: Provided is a novel compound represented by the following formula wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor ? agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or metabolic diseases such as diabetes and the like, and the like.Type: ApplicationFiled: October 22, 2013Publication date: February 13, 2014Applicant: Takeda Pharmaceutical Company LimitedInventors: Tsuyoshi Maekawa, Hideyuki Igawa
-
Patent number: 8592431Abstract: Provided is a novel compound represented by the following formula Wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor ? agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or metabolic diseases such as diabetes and the like, and the like.Type: GrantFiled: January 29, 2010Date of Patent: November 26, 2013Assignee: Takeda Pharmaceutical Company LimitedInventors: Tsuyoshi Maekawa, Hideyuki Igawa
-
Patent number: 8328973Abstract: Disclosed is a method of manufacturing a radial tire for a construction vehicle, wherein when a cylindrical band is formed by using one layer of carcass layer formed of steel cords in a band making step, a shape retaining layer formed of at least one layer of organic fiber cords is wrapped on the outer peripheral surface of the carcass layer so that the organic fiber cords cross the steel cords of the carcass layer. The radial tire having excellent uniformity without any uneven widening between the steel cords can be provided without using a shape retaining auxiliary apparatus.Type: GrantFiled: October 1, 2004Date of Patent: December 11, 2012Assignee: The Yokohama Rubber Co., Ltd.Inventors: Ken Takahashi, Kazuo Teramoto, Tsuyoshi Maekawa
-
Patent number: 8283353Abstract: Provided is a novel compound represented by the following formula Wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor ? agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or metabolic diseases such as diabetes and the like, and the like.Type: GrantFiled: January 29, 2010Date of Patent: October 9, 2012Assignee: Takeda Pharmaceutical Company LimitedInventors: Tsuyoshi Maekawa, Hideyuki Igawa
-
Patent number: 8148383Abstract: Provided is a novel compound represented by the following formula Wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor ? agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or metabolic diseases such as diabetes and the like, and the like.Type: GrantFiled: January 29, 2010Date of Patent: April 3, 2012Assignee: Takeda Pharmaceutical Company LimitedInventors: Tsuyoshi Maekawa, Hideyuki Igawa
-
Publication number: 20120052592Abstract: The present invention has its main object of providing a method for determining prognosis scientifically by searching an early marker for predicting neurological prognosis in order to grasp the disease state of a patient with an acute central nervous system disorder in the early stage and enabling an appropriate treatment to be performed. The method for determining the prognosis is provided in which the expression level of SH3BGRL3 in the biological fluid of the patient within 48 hours after resuscitation from cardiopulmonary arrest is measured, and the prognosis of the disorder classified into a good prognosis group and a poor prognosis group depending on the expression level or the presence or absence of the expression based on the Glasgow Outcome Scale (GOS) is predicted.Type: ApplicationFiled: March 27, 2008Publication date: March 1, 2012Applicants: NANO SOLUTION, INC.,, YAMAGUCHI UNIVERSITYInventors: Tsuyoshi Maekawa, Tomonori Izumi, Yasutaka Oda, Yuki Akiyoshi
-
Publication number: 20110294832Abstract: Provided is a novel compound represented by the following formula Wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor ? agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or metabolic diseases such as diabetes and the like, and the like.Type: ApplicationFiled: August 9, 2011Publication date: December 1, 2011Inventors: Tsuyoshi Maekawa, Hideyuki Igawa
-
Publication number: 20110288087Abstract: Provided is a novel compound represented by the following formula Wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor ? agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or metabolic diseases such as diabetes and the like, and the like.Type: ApplicationFiled: January 29, 2010Publication date: November 24, 2011Inventors: Tsuyoshi Maekawa, Hideyuki Igawa
-
Patent number: 7998968Abstract: A compound represented by the formula (I): wherein R1 is an oxo group, ?N—R or the like; a group represented by the formula: is a group represented by the formula: R2 is a group represented by the formula: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, —CO—R8 or —O—R8?, or a salt thereof. For example, the compound may be substituted pyrimidines and pharmaceutical compositions of the formula (I) where X=—CR3; X1=—CR2 or —NR2; and X2=—CR5 or —NR5. The compound of the present invention is useful as a drug for the prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases.Type: GrantFiled: November 25, 2009Date of Patent: August 16, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Takanobu Kuroita, Hiroki Sakamoto, Hideyuki Igawa, Minoru Sasaki, Kouhei Asano, Tsuyoshi Maekawa, Koji Fuji